Home › New Data from Phase 2 Study Evaluating KEYTRUDA (pembrolizumab) for the Treatment of Cancers Deficient in DNA Mismatch Repair Show Durable Responses Across a Range of Cancers
 

Keywords :   


New Data from Phase 2 Study Evaluating KEYTRUDA (pembrolizumab) for the Treatment of Cancers Deficient in DNA Mismatch Repair Show Durable Responses Across a Range of Cancers

2016-06-05 19:43:00| Merck.com - Research & Development News

Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced updated findings from a study evaluating KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, in patients with advanced cancers characterized as deficient for DNA mismatch repair (MMR). Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Kim Hamilton, 908-740-1863orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: of show data range

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
30.06Atlantic Tropical Weather Outlook
30.06Eastern North Pacific Tropical Weather Outlook
30.06Hurricane Beryl Graphics
30.06Hurricane Beryl Public Advisory Number 6A
30.06Summary for Hurricane Beryl (AT2/AL022024)
30.06Hurricane Beryl Graphics
30.06Hurricane Beryl Wind Speed Probabilities Number 6
30.06Hurricane Beryl Public Advisory Number 6
More »